List of Excipients in Branded Drug GOCOVRI

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Supernus Pharmaceuticals	GOCOVRI	amantadine	17772-085	CELLULOSE, MICROCRYSTALLINE
Supernus Pharmaceuticals	GOCOVRI	amantadine	17772-085	COPOVIDONE K25-31
Supernus Pharmaceuticals	GOCOVRI	amantadine	17772-085	ETHYLCELLULOSE
Supernus Pharmaceuticals	GOCOVRI	amantadine	17772-085	HYPROMELLOSE 2910
Supernus Pharmaceuticals	GOCOVRI	amantadine	17772-085	MAGNESIUM STEARATE

Gocovri Excipient Strategy and Commercial Opportunities

Last updated: August 11, 2026

Gocovri is an extended-release amantadine hydrochloride capsule whose commercial value depends on controlled drug release, bedtime dosing, and differentiation from low-cost immediate-release amantadine. Its excipient strategy supports multiparticulate or coated-particle delivery rather than a simple powder-filled capsule. The strongest commercial opportunities are in generic-equivalent manufacturing, alternate controlled-release platforms, capsule-shell and coating supply, patient-friendly dosage forms, and 505(b)(2) reformulations.

Gocovri is marketed by Supernus Pharmaceuticals after Supernus acquired Adamas Pharmaceuticals in 2021. FDA approved Gocovri in 2017 for dyskinesia associated with Parkinson's disease and expanded its indication in 2021 to include OFF episodes in Parkinson's disease patients receiving levodopa-based therapy.[1,2]

What is Gocovri and how does its formulation work?

Gocovri contains amantadine hydrochloride in extended-release capsules administered once daily at bedtime. The approved strengths are 68.5 mg and 137 mg. The recommended starting dose is 137 mg at bedtime, with a possible reduction to 68.5 mg based on tolerability and renal function.[1]

The formulation is designed to produce higher amantadine exposure during the daytime, when dyskinesia and OFF episodes commonly create clinical problems. Immediate-release amantadine generally requires multiple daily doses and produces a different concentration-time profile.

Gocovri formulation profile

Attribute	Gocovri
Active ingredient	Amantadine hydrochloride
Dosage form	Extended-release hard gelatin capsule
Strengths	68.5 mg and 137 mg
Administration	Once daily at bedtime
Primary indications	Parkinson's disease dyskinesia; OFF episodes
FDA application	NDA 208944
Initial U.S. approval	August 2017
Expanded indication	February 2021
Marketing company	Supernus Pharmaceuticals
Product category	Extended-release CNS drug

The formulation is commercially differentiated by release timing rather than by a new active ingredient. That distinction creates both opportunity and risk for excipient suppliers. A supplier must support reproducible release kinetics, not only acceptable powder flow and capsule fill.

What excipients are used in Gocovri capsules?

The FDA prescribing information identifies the inactive ingredients as colloidal silicon dioxide, ethylcellulose, gelatin, hypromellose, magnesium stearate, microcrystalline cellulose, povidone, sucrose, talc, and titanium dioxide.[1]

The excipients can be grouped by functional role.

Excipient	Likely formulation role
Ethylcellulose	Water-insoluble release-controlling polymer or coating component
Hypromellose	Film-forming polymer, capsule-related material, or release-control component
Povidone	Binder and granulation aid
Sucrose	Pellet or core material in a multiparticulate system
Microcrystalline cellulose	Diluent, carrier, and structural excipient
Magnesium stearate	Lubricant
Colloidal silicon dioxide	Glidant and moisture-management aid
Talc	Anti-adherent and coating aid
Gelatin	Hard capsule shell
Titanium dioxide	Opacifier and color-system component

The public labeling identifies the ingredients but does not provide the complete manufacturing process, polymer grades, coating weight gains, particle-size specifications, or dissolution targets. Those process parameters are central to bioequivalence and are generally controlled through confidential manufacturing information and product-specific development work.

Which excipients create the largest commercial opportunity?

The highest-value opportunities are controlled-release polymers and multiparticulate processing materials.

Ethylcellulose and hypromellose

Ethylcellulose is commercially important because it can create a water-insoluble barrier that slows amantadine release. Hypromellose can provide film formation, matrix control, viscosity management, and capsule-related functionality. Suppliers with multiple viscosity grades and validated coating systems can target both abbreviated new drug application developers and contract manufacturers.

The opportunity is not limited to selling raw polymer. Higher-value services include:

• Polymer grade selection
• Aqueous and organic coating process development
• Coating uniformity control
• Dissolution-profile matching
• Scale-up from laboratory fluid-bed equipment
• Stability support under ICH conditions
• Regulatory support for excipient qualification

A polymer supplier that can demonstrate interchangeable performance across manufacturing scales has greater commercial leverage than a commodity excipient distributor.

Sucrose-based cores and multiparticulate systems

Sucrose and microcrystalline cellulose may support inert cores, drug layering, or pellet formation. Multiparticulate systems are attractive because they can divide the dose across many coated units. This approach can reduce the impact of local defects in an individual particle and may provide more consistent gastrointestinal distribution than a single monolithic matrix.

Commercial suppliers can compete through:

• Uniform neutral starter pellets
• Narrow particle-size distributions
• Low friability
• Consistent surface morphology
• Drug-layering compatibility
• High-throughput fluid-bed processing
• Reduced agglomeration during coating

The critical performance metric is dissolution reproducibility after scale-up, not merely pellet appearance.

Povidone, microcrystalline cellulose, and colloidal silicon dioxide

These excipients are less differentiated individually but remain important for manufacturing robustness. Povidone affects binding and granule strength. Microcrystalline cellulose affects bulk density, capsule filling, and mechanical properties. Colloidal silicon dioxide affects flow and may reduce problems associated with cohesive amantadine-containing blends.

The commercial opportunity lies in formulation optimization and supply reliability. Alternate grades may be useful when a manufacturer seeks a second source, but each grade change can affect blend uniformity, coating behavior, capsule fill weight, and dissolution.

How does Gocovri compare with immediate-release amantadine?

Gocovri competes with generic immediate-release amantadine hydrochloride, but the products are not interchangeable on a formulation basis. Gocovri's differentiation is the extended-release profile and once-daily bedtime administration.

Commercial factor	Gocovri	Immediate-release amantadine
Dosing pattern	Once nightly	Usually multiple daily doses
Release profile	Extended release	Immediate release
Active ingredient	Amantadine hydrochloride	Amantadine hydrochloride
Generic competition	Limited to equivalent ER products	Broad generic competition
Primary differentiation	Exposure timing and convenience	Low price and availability
Excipient complexity	High	Lower
Manufacturing barrier	Controlled-release development and bioequivalence	Conventional oral solid-dose manufacturing
Payer pressure	Higher branded-product exposure	Strong generic substitution

The formulation creates a commercial barrier that does not exist for conventional amantadine capsules or tablets. A company that can reproduce the release profile at a lower cost may compete directly. A company that cannot match the profile may instead pursue an alternative product under section 505(b)(2) of the Federal Food, Drug, and Cosmetic Act.

What formulation patents protect Gocovri?

Gocovri's protection is principally associated with extended-release amantadine formulations, release profiles, dosage regimens, and related product characteristics. The relevant patent estate should be assessed through the current FDA Orange Book listing for NDA 208944, USPTO records, and litigation filings.[3,4]

The protection strategy generally falls into four categories:

1. Composition and formulation claims covering extended-release amantadine dosage forms.
2. Release-profile claims covering the timing or extent of amantadine release.
3. Method-of-use claims covering dyskinesia or OFF episodes in Parkinson's disease.
4. Manufacturing claims covering coated particles, multiparticulate systems, or controlled-release processing.

The commercial significance of the excipient system is that a competitor may avoid a narrowly drafted composition claim by using a different polymer, matrix technology, or particle architecture. It may still face method-of-use or release-profile claims if the proposed product produces substantially similar clinical exposure and is labeled for the same indications.

Orange Book status and Paragraph IV exposure

FDA's Orange Book is the controlling public source for listed patents and regulatory exclusivity associated with NDA 208944.[3] A generic applicant seeking approval before listed patent expiry may submit a Paragraph IV certification. The patent holder can then initiate litigation within the statutory period, potentially triggering a 30-month stay of approval under the Hatch-Waxman framework.

For Gocovri, the most material Paragraph IV risks are likely to involve:

• Whether the proposed generic uses the same or equivalent release-control mechanism.
• Whether the product meets the same dissolution profile.
• Whether a coating or multiparticulate design falls within formulation claims.
• Whether the proposed labeling induces infringement of method-of-use claims.
• Whether the generic applicant can establish non-infringement through a different excipient architecture.

A formulation change that replaces ethylcellulose with another release-control polymer may reduce composition-claim exposure, but it can increase development risk because the alternative product still must demonstrate bioequivalence and acceptable clinical performance.

When does Gocovri lose exclusivity?

Gocovri does not have a single practical loss-of-exclusivity date. Commercial entry depends on FDA regulatory exclusivity, listed patent expiry, patent litigation, settlement terms, and the timing of ANDA approvals.

The key milestones are:

Exclusivity element	Business significance
New chemical entity exclusivity	Generally not applicable because amantadine was previously approved
New indication exclusivity	May protect the approved indication for a defined period
Listed formulation patents	Can delay ANDA approval or trigger litigation
Method-of-use patents	Can affect labeling and carve-out strategy
Patent settlements	May establish an agreed generic entry date
ANDA approval	Does not always equal immediate commercial launch
Commercial launch	Depends on patent risk, supply, payer access, and economics

A precise launch forecast requires the live Orange Book record and current court or settlement information. The decisive question is not when the original Gocovri approval occurred, but when enforceable formulation and use claims no longer block an equivalent extended-release product.

What generic entry risks exist for Gocovri?

Generic entry risk is moderate to high over the long term but is more technically difficult than entry against immediate-release amantadine.

Technical barriers

An ANDA applicant must address:

• Extended-release dissolution across multiple pH conditions
• Dose proportionality between 68.5 mg and 137 mg strengths
• Food-effect performance
• Stability of coated particles or matrix units
• Capsule-fill uniformity
• Renal-dose considerations reflected in labeling
• In vitro-in vivo correlation where relevant
• Bioequivalence under fasting and fed conditions

Amantadine is a relatively established active ingredient, which limits active-ingredient risk. The main development burden lies in reproducing the clinical exposure profile.

Regulatory barriers

A generic applicant may use a Paragraph IV certification against listed patents, a section viii statement to omit certain method-of-use claims, or a combination of certifications depending on the Orange Book record. A label carve-out may be commercially unattractive if the omitted indication represents a meaningful portion of prescriptions.

An alternative 505(b)(2) product could pursue a different release profile, dosage form, or administration schedule. That pathway may offer greater formulation flexibility but can create additional clinical and patent exposure.

What excipient supply opportunities exist for Gocovri competitors?

The most attractive opportunities are linked to development and scale-up rather than the supply of basic ingredients.

Opportunity map

Opportunity	Target customer	Commercial rationale
Controlled-release polymer supply	Generic developers and CDMOs	Supports dissolution matching
Neutral pellet supply	Multiparticulate manufacturers	Reduces internal development time
Fluid-bed coating services	Specialty CDMOs	Converts formulation know-how into manufacturing capacity
Alternate-grade qualification	Originator and generic manufacturers	Reduces single-source risk
Capsule-shell supply	Capsule manufacturers	Supports color, opacity, and supply continuity
Analytical dissolution services	ANDA and 505(b)(2) developers	Required for formulation comparison
Particle-engineering platforms	Specialty drug developers	Enables differentiated release profiles
Sprinkle or modified capsule products	Lifecycle-management companies	Improves administration flexibility
Pediatric or swallowing-friendly systems	Specialty pharmaceutical companies	Expands patient-access options

Suppliers should prioritize excipients with established compendial status, broad regulatory histories, and strong lot-to-lot consistency. A new excipient may provide technical advantages but creates a heavier regulatory burden.

What lifecycle-management opportunities exist for Gocovri?

Gocovri's excipient platform may support several follow-on products.

Sprinkle capsule or capsule-opening formulation

A capsule that can be opened and sprinkled onto soft food could address swallowing difficulty in Parkinson's disease. The formulation would require data showing that opening the capsule does not alter release kinetics, dose uniformity, or stability. Taste masking and protection against chewing would be important.

Lower-dose strengths

A lower-strength capsule could support renal impairment, titration, or patients who do not tolerate 137 mg. Because amantadine clearance is highly dependent on renal function, dose flexibility has clinical and commercial value.[1]

Alternative controlled-release profiles

A developer could pursue a morning formulation, twice-daily product, or longer-duration product. These products would not necessarily be substitutable for Gocovri, but they could target different dosing preferences and OFF-episode patterns.

Combination products

A fixed-dose product combining amantadine with another Parkinson's therapy would require substantial clinical and regulatory work. The opportunity is more strategic than immediate because dose matching, drug-drug interaction, and intellectual-property issues would be complex.

How strong is the Gocovri patent estate?

The patent estate is strongest where formulation structure, release kinetics, and approved use overlap. It is weaker against a technically distinct controlled-release system that achieves a different release mechanism and avoids protected indications.

Patent strength should be evaluated across five dimensions:

Dimension	Assessment
Active ingredient	Weak protection because amantadine is an established drug
Extended-release technology	Primary protection area
Excipient composition	Depends on claim specificity and prosecution history
Method of use	Potentially significant for Parkinson's indications
Manufacturing process	Can create additional barriers if claims cover coated-particle production

An excipient substitution does not automatically avoid infringement. The legal analysis turns on the patent claims, equivalents doctrine, product architecture, and proposed label. It also does not guarantee bioequivalence.

What revenue exposure does generic Gocovri create?

Gocovri's revenue exposure is concentrated in a branded extended-release product with no active-ingredient exclusivity. Generic entry could produce a rapid price decline if multiple ANDA products launch, particularly after the first commercial entrant receives meaningful market access.

Supernus reports Gocovri as one of its commercial products and provides product-level sales information in its annual filings.[5] The revenue impact of generic entry will depend on:

• The number of approved competitors
• First-filer exclusivity
• Payer formulary placement
• Patient persistence with once-nightly dosing
• The ability of generics to match both strengths
• Whether the originator retains favorable specialty-pharmacy access
• The presence of authorized or branded-generic alternatives

A single generic with limited supply may cause less erosion than several interchangeable products. The highest-risk scenario is simultaneous entry by several manufacturers with equivalent labeling and reliable controlled-release manufacturing.

What geographic commercial opportunities exist?

The United States is the principal reference market for Gocovri's formulation and patent strategy. Outside the U.S., opportunities depend on national patent terms, local regulatory pathways, data exclusivity, and whether the product is registered as an extended-release amantadine capsule.

Excipient suppliers can pursue global opportunities through:

• European and Canadian controlled-release product development
• Regional CDMO partnerships
• Local sourcing of compendial polymers
• Technical-transfer packages for multiparticulate manufacturing
• Stability programs addressing climate-zone requirements
• Regulatory documentation for excipient provenance and quality

The global opportunity is constrained by the relatively narrow Parkinson's dyskinesia market, but the same controlled-release technology can be adapted to other CNS drugs.

Key Takeaways

• Gocovri is an extended-release amantadine hydrochloride capsule approved for Parkinson's disease dyskinesia and OFF episodes.
• Its commercial differentiation comes from once-nightly dosing and daytime exposure, not from a new active ingredient.
• Ethylcellulose, hypromellose, sucrose, povidone, and microcrystalline cellulose are the most commercially relevant excipient classes.
• The principal technical barrier is dissolution and pharmacokinetic matching, especially for multiparticulate or coated-particle systems.
• Generic competition is more difficult than for immediate-release amantadine but remains commercially credible after enforceable patent barriers expire.
• The strongest supplier opportunities involve polymer systems, pellet cores, fluid-bed coating, analytical support, and alternate-grade qualification.
• Lifecycle opportunities include sprinkle capsules, lower strengths, alternative release profiles, and other patient-friendly dosage forms.
• Patent and launch timing must be assessed against the current Orange Book, USPTO records, court dockets, and company disclosures.

FAQs

Can Gocovri use the same excipients as immediate-release amantadine?

It can use overlapping excipients, but an equivalent extended-release product requires a different release-control strategy. Immediate-release excipients generally do not reproduce Gocovri's pharmacokinetic profile without additional formulation technology.

Is ethylcellulose essential to a generic Gocovri product?

No. A generic developer may use another polymer or release-control platform if it meets regulatory requirements and avoids applicable patent claims. Ethylcellulose may remain commercially attractive because of its established use in controlled-release coatings.

Can Gocovri capsules be opened and sprinkled on food?

The approved labeling should control administration. A sprinkle formulation would require separate development and regulatory support because opening the capsule could change release performance or dose delivery.

Is a 505(b)(2) product a direct generic substitute for Gocovri?

No. A 505(b)(2) product may use a different formulation, strength, release profile, or administration method. It can compete commercially without being an ANDA-equivalent product, but it may require additional clinical or bridging evidence.

Which excipient suppliers are best positioned for Gocovri-related opportunities?

Suppliers with validated ethylcellulose or hypromellose grades, neutral starter pellets, fluid-bed coating capability, dissolution laboratories, and regulatory support have the strongest positioning. Commodity suppliers of lubricants or diluents face lower margins and less differentiation.

References

1. U.S. Food and Drug Administration. (2024). Gocovri (amantadine) extended-release capsules: Prescribing information.
2. U.S. Food and Drug Administration. (2021). FDA approves expanded indication for Gocovri for OFF episodes in Parkinson's disease.
3. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book.
4. United States Patent and Trademark Office. (2024). Patent Center and Patent Examination Data System records.
5. Supernus Pharmaceuticals, Inc. (2024). Annual report on Form 10-K.